This 2024 clinical study assessed the effectiveness of a topical antioxidant serum containing 0.5% silymarin, 15% L-ascorbic acid, 0.5% ferulic acid, and 0.5% salicylic acid in treating facial acne. In a 12-week Brazilian trial (n=56), the serum achieved a 45% reduction in inflammatory lesions and a 43% reduction in non-inflammatory
This 2023 prospective, open-label pilot study assessed the efficacy and safety of a 0.5% silymarin-loaded antioxidant serum (SAS) as an adjunct treatment in 22 Korean patients with mild-to-moderate acne vulgaris. Over four weeks, patients applied the serum twice daily in addition to their regular acne treatments. The study reported reductions
This 2017 review evaluates the role of phytochemicals in the chemoprevention of melanoma, discussing their mechanisms in modulating critical molecular pathways such as MAPK, PI3K/AKT, and NF-κB. Compounds like fisetin, EGCG, resveratrol, curcumin, and silymarin are shown to inhibit melanoma cell proliferation, induce apoptosis, and suppress metastasis in preclinical models.
This meta-analysis reviewed the effects of silymarin supplementation on liver and kidney functions by analyzing data from 41 randomized controlled trials. The results showed significant reductions in liver enzymes (alkaline phosphatase, alanine transaminase, aspartate aminotransferase) and creatinine levels, as well as increased serum glutathione levels. Longer-duration and higher-dose silymarin supplementation
This narrative review discusses the hepatoprotective benefits of silymarin, an extract from milk thistle, in treating liver diseases such as cirrhosis, non-alcoholic fatty liver disease, and drug-induced liver injury. Clinical studies demonstrated that silymarin reduces oxidative stress, improves liver function, and offers potential benefits in glycemic control for patients with
This systematic review evaluates the clinical efficacy and safety of silymarin, a flavonoid complex from milk thistle, in treating liver diseases such as Amanita phalloides poisoning, alcoholic liver disease, and cirrhosis. The review analyzed 36 studies, showing that silymarin significantly reduced liver-related mortality by 7% in cirrhosis patients (p
This randomized, double-blind, placebo-controlled trial evaluated the efficacy of silymarin in patients with nonalcoholic steatohepatitis (NASH). While silymarin did not significantly reduce the NAFLD activity score (NAS) by 30% or more compared to placebo, it was associated with a significant reduction in liver fibrosis as measured by both histology and
